Par Pharmaceutical Companies Inc (PRX) financial statements (2022 and earlier)
Company profile
| Business Address |
ONE RAM RIDGE ROAD CHESTNUT RIDGE, NY 10977 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 244 | 134 | ||
| Cash and cash equivalents | 244 | 130 | ||
| Short-term investments | 4 | |||
| Receivables | 159 | 143 | ||
| Inventory, net of allowances, customer advances and progress billings | 155 | 117 | ||
| Inventory | 155 | 117 | ||
| Income taxes receivable | ✕ | 1 | ||
| Other undisclosed current assets | 95 | 70 | ||
| Total current assets: | 653 | 466 | ||
| Noncurrent Assets | ||||
| Property, plant and equipment | 217 | 127 | ||
| Intangible assets, net (including goodwill) | 2,053 | 1,942 | ||
| Goodwill | 1,012 | 850 | ||
| Intangible assets, net (excluding goodwill) | 1,041 | 1,093 | ||
| Other noncurrent assets | 84 | 96 | ||
| Total noncurrent assets: | 2,354 | 2,166 | ||
| TOTAL ASSETS: | 3,007 | 2,631 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 167 | 67 | ||
| Accounts payable | 80 | 31 | ||
| Accrued liabilities | 48 | 15 | ||
| Employee-related liabilities | 32 | 21 | ||
| Interest and dividends payable | 8 | |||
| Debt | 15 | 21 | ||
| Estimated litigation liability | 41 | |||
| Other undisclosed current liabilities | 96 | 129 | ||
| Total current liabilities: | 278 | 259 | ||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | 1,904 | 1,516 | ||
| Long-term debt, excluding current maturities | 1,904 | 1,516 | ||
| Liabilities, other than long-term debt | 247 | 289 | ||
| Deferred tax liabilities, net | 247 | 289 | ||
| Other undisclosed noncurrent liabilities | (2,134) | (1,785) | ||
| Total noncurrent liabilities: | 17 | 20 | ||
| Total liabilities: | 295 | 279 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent | 561 | 547 | ||
| Additional paid in capital | 809 | 687 | ||
| Accumulated other comprehensive loss | (4) | (1) | ||
| Accumulated deficit | (244) | (138) | ||
| Total stockholders' equity: | 561 | 547 | ||
| Other undisclosed liabilities and equity | 2,151 | 1,805 | ||
| TOTAL LIABILITIES AND EQUITY: | 3,007 | 2,631 | ||
Income statement (P&L) ($ in millions)
| 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|
| Other undisclosed net loss attributable to parent | (106) | ||
| Net loss available to common stockholders, diluted: | (106) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.